Терапевтический архив (Jul 2021)

Repeated haploidentical allogeneic hematopoietic stem cell transplantation with TCR αβ/CD19 depletion in patient with primary myelofibrosis. Case report

  • Elmira I. Kolgaeva,
  • Vera A. Vasilyeva,
  • Larisa A. Kuzmina,
  • Mikhail Yu. Drokov,
  • Mariya V. Dovydenko,
  • Zoya V. Konova,
  • Dmitry I. Chebotarev,
  • Alla M. Kovrigina,
  • Denis V. Kamelskih,
  • Tatyana V. Gaponova,
  • Manana A. Sokolova,
  • Irina N. Subortseva,
  • Anait L. Melikyan,
  • Mikhail A. Maschan,
  • Elena N. Parovichnikova,
  • Valerii G. Savchenko

DOI
https://doi.org/10.26442/00403660.2021.07.200948
Journal volume & issue
Vol. 93, no. 7
pp. 805 – 810

Abstract

Read online

Indications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with primary myelofibrosis are intermediate-2 and high-risk group of DIPSS (Dynamic International Prognostic Scoring System), beginning of the disease in childhood. The other adverse factors affect engraftment and survival after allo-HSCT, example partialy matched donor. But the result of allo-HSCT from matched related donors and result of allo-HSCT from haploidentical donors are comparable. The method for haploidentical hematopoietic stem cell transplantation is T-cell-depletion. This is clinical case of T-cell-depleted haploidentical hematopoietic stem cell transplantation in patient with primary myelofibrosis, the diagnosis was established in childhood.

Keywords